A regulatory perspective on in vitro diagnostics

Nature Biotechnology

Volumn 24, Issue 8, 2006, Pages 927-929

  Gottlieb, Scott ^a   Woodcock, Janet ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE;

CLINICAL PRACTICE; CLINICAL TRIAL; DECISION MAKING; DIAGNOSTIC PROCEDURE; DNA MICROARRAY; DRUG RESPONSE; DRUG SELECTIVITY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEALTH PROGRAM; HORMONAL THERAPY; HUMAN; IN VITRO STUDY; MEDICAL PRACTICE; MEDICAL TECHNOLOGY; NOTE; ONCOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUBLIC HEALTH; SAFETY; SCIENCE;

DEVICE APPROVAL; DIAGNOSTIC TECHNIQUES AND PROCEDURES; DRUG APPROVAL; GOVERNMENT REGULATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33747048091     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0806-927     Document Type: Note

References (8)

1. Tobin, C. Hosp. Management Int. 75-79 (2003).
2. McGuire, L. Cancer 36, 638-644 (1975).
3. Lesko, L. & Woodcock, J. Nat. Rev. Drug Discov. 3, 763-770 (2004).
4. http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf
5. Lesko, L.J. & Salerno, R.A. Pharmacogenomics 5, 503-505 (2004).
6. Lesko, L.J. & Salerno, R.A. Pharmacogenomics 5, 25-30 (2004).
7. Gutman, S. Clin. Chem. 45, 746-749 (1999).
8. Lesko, L.J. et al. J. Clin. Pharmacol. 43, 342-358 (2003).